Skip to content

Study · Case report or series · n = 1 · 2026

4 results

Glucagon-Like Peptide-1 Receptor Agonists in the Management of Mitochondrial Diabetes in an Adolescent: A Case Report.

Hayes E, Nillsen A, Rowe PW, Siafarikas A, Abraham MB

Hormone research in paediatrics18 Apr 2026

PMID41999618 (opens in a new tab)DOI10.1159/000552014 (opens in a new tab)PepBankPUB-41999618
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In an adolescent girl with mitochondrial diabetes, HbA1c fell from 13.7% to 5.6% over 7 months of weekly semaglutide.

    In plain wordsIn one adolescent girl with mitochondrial diabetes, HbA1c fell from 13.7% to 5.6% over 7 months of weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.25 mg weekly · subcutaneous · 7 monthsAs given in this study (human).

    Measurements

    HbA1c baseline
    13.7%
    start
    HbA1c follow-up
    5.6%
    7 months

    Source sentences

    Summary
    Treatment with 0.25 mg semaglutide SC weekly led to a reduction in HbA1c from 13.7% (126 mmol/mol) to 5.6% (38 mmol/mol) over a 7-month period.
    2 context sentences
    Summary · context
    A 16-year-old adolescent girl with a genetically confirmed diagnosis of MELAS due to an m.3243A>G variant presented with clinical and biochemical features of diabetes.
    Summary · context
    She was successfully transitioned from subcutaneous insulin therapy to weekly GLP-1RA monotherapy shortly after diagnosis of diabetes.
  2. 02HumanCase report or seriesEfficacy outcome

    In an adolescent girl with mitochondrial diabetes, insulin was completely stopped within 5 days of starting semaglutide.

    In plain wordsOne adolescent girl with mitochondrial diabetes stopped insulin completely within 5 days of starting semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseInsulin cessation
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.25 mg weekly · subcutaneous · 5 daysAs given in this study (human).

    Source sentences

    Summary
    Insulin was completely ceased within 5 days of starting semaglutide.
    2 context sentences
    Summary · context
    A 16-year-old adolescent girl with a genetically confirmed diagnosis of MELAS due to an m.3243A>G variant presented with clinical and biochemical features of diabetes.
    Summary · context
    She was successfully transitioned from subcutaneous insulin therapy to weekly GLP-1RA monotherapy shortly after diagnosis of diabetes.
  3. 03HumanCase report or seriesEfficacy outcome

    In an adolescent girl with mitochondrial diabetes, continuous glucose monitoring over 11 months of follow-up met glycaemic targets.

    In plain wordsOne adolescent girl with mitochondrial diabetes met her glucose targets on continuous monitoring over 11 months of follow-up.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedContinuous glucose monitoring targets
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.25 mg weekly · subcutaneous · 11 monthsAs given in this study (human).

    Source sentences

    Summary
    CGM data from a 11 months follow-up period are presented, which demonstrate CGM data meeting glycaemic targets.
    2 context sentences
    Summary · context
    A 16-year-old adolescent girl with a genetically confirmed diagnosis of MELAS due to an m.3243A>G variant presented with clinical and biochemical features of diabetes.
    Summary · context
    She was successfully transitioned from subcutaneous insulin therapy to weekly GLP-1RA monotherapy shortly after diagnosis of diabetes.
  4. 04HumanCase report or seriesSafety outcome

    In an adolescent girl with mitochondrial diabetes, low-dose semaglutide was well tolerated without lactic acidosis.

    In plain wordsOne adolescent girl with mitochondrial diabetes tolerated low-dose semaglutide well, without lactic acidosis.

    Peptide
    Semaglutide
    Outcome
    No significant changeTolerability and lactic acidosis
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    0.25 mg weekly · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Low-dose semaglutide 0.25 mg sc weekly was efficacious and well tolerated without lactic acidosis.
    2 context sentences
    Summary · context
    A 16-year-old adolescent girl with a genetically confirmed diagnosis of MELAS due to an m.3243A>G variant presented with clinical and biochemical features of diabetes.
    Summary · context
    She was successfully transitioned from subcutaneous insulin therapy to weekly GLP-1RA monotherapy shortly after diagnosis of diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.